Immunogenic composition
US-2024238398-A1 · Jul 18, 2024 · US
US9408899B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9408899-B2 |
| Application number | US-201113823668-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 3, 2011 |
| Priority date | Nov 4, 2010 |
| Publication date | Aug 9, 2016 |
| Grant date | Aug 9, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a plurality of peptides, wherein the plurality of peptides comprises a first peptide with the amino acid sequence KSFKDILPK (SEQ ID NO: 4), a second peptide with the amino acid sequence RSFKDLLKK (SEQ ID NO: 6), and a third peptide with the amino acid sequence AKFVAAWTLKAAA (SEQ ID NO: 7), wherein the plurality of peptides are linked to form a chimeric polypeptide. 2. The composition of claim 1 , wherein the composition comprises an oil-in-water emulsion that includes a synthetic adjuvant monophosphorvl lipid A (MLA). 3. The composition of claim 1 wherein the plurality of peptides further comprises one or more of AVVSLLRLLK (SEQ ID NO:23), STFWPCLLR (SEQ ID NO:21), and SSAYVFSVK (SEQ ID NO:22). 4. The composition of claim 3 , further comprising an adjuvant. 5. The composition of claim 3 wherein the plurality of peptides further comprises one or more of FLSLSLLVI (SEQ ID NO: 11) FMIAFISCFA (SEQ ID NO: 12), FVIFACNFV (SEQ ID NO: 16), FMIVSISLY (SEQ ID NO: 13), FLLGLLVHV (SEQ ID NO: 15), FLTDYIPGA (SEQ ID NO: 14), ITMGSLFFV (SEQ ID NO: 17), GLAAAVYAV (SEQ ID NO: 18), VLLPVLFGV (SEQ ID NO: 20), FAAAFFPAV (SEQ ID NO: 19), VVFVVFMGV (SEQ ID NO: 1), FMGVLVNSL (SEQ ID NO: 2), FLVPFVVFL (SEQ ID NO: 3), AMLTAFFLR (SEQ ID NO: 5), LPOFATAAT (SEQ ID NO: 8), VPFVVFLVA (SEQ ID NO: 9), and HF10 (HPGSVNEFDF (SEQ ID NO: 10)). 6. The composition of claim 5 , further comprising an adjuvant. 7. The composition of claim 1 wherein the plurality of peptides further comprises one or more of FLSLSLLVI (SEQ ID NO: 11), FMIAFISCFA (SEQ ID NO: 12), FVIFACNFV (SEQ ID NO: 16), FMIVSISLV (SEQ ID NO: 13), FLLGLLVHV (SEQ ID NO: 15), FLTDYIPGA (SEQ ID NO: 14), ITMGSLFFV (SEQ ID NO: 17), GLAAAVVAV (SEQ ID NO: 18), VLLPVLFGV (SEQ ID NO: 20), FAAAFFPAV (SEQ ID NO: 19), VVFVVFMGV (SEQ ID NO: 1), FMGVLVNSL (SEQ ID NO: 2), FLVPFVVFL (SEQ ID NO: 3), AMLTAFFLR (SEQ ID NO: 5), LPQFATAAT (SEQ ID NO: 8), VPFVVFLVA (SEQ ID NO: 9), and HF10 (HPGSVNEFDF (SEQ ID NO: 10)). 8. The composition of claim 7 , further comprising an adjuvant. 9. The composition of claim 1 further comprising an adjuvant.
Protozoa antigens · CPC title
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title
Proteins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.